Neumora Therapeutics, Inc.·4

Feb 20, 5:14 PM ET

BERNS PAUL L 4

4 · Neumora Therapeutics, Inc. · Filed Feb 20, 2025

Insider Transaction Report

Form 4
Period: 2025-02-18
BERNS PAUL L
DirectorSee Remarks
Transactions
  • Sale

    Common Stock

    2025-02-18$1.69/sh13,871$23,4687,405,004 total
Holdings
  • Common Stock

    (indirect: See footnote)
    133,097
  • Common Stock

    (indirect: See footnote)
    133,097
  • Common Stock

    (indirect: See footnote)
    133,097
Footnotes (5)
  • [F1]The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on April 19, 2024, which provides for the automatic sale of shares of common stock that would otherwise be issuable on each vesting date of a covered restricted stock unit in an amount necessary to satisfy the applicable withholding obligation.
  • [F2]This transaction was executed in multiple trades in prices ranging from $1.66 to $1.745, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
  • [F3]Held by LULU TRUST OF 2024 FBO AB.
  • [F4]Held by LULU TRUST OF 2024 FBO OB.
  • [F5]Held by LULU TRUST OF 2024 FBO HB.

Documents

1 file
  • 4
    form4.xmlPrimary